Cost-effectiveness of telaprevir in patients with genotype 1 hepatitis C in australia

Value in Health

Volumn 17, Issue 8, 2014, Pages 792-800

  Warren, Emma ^a   Wright, Alison ^b   Jones, Brandon ^b  

^a Health Economist   (Australia)

^b Janssen Australia Pty Ltd   (Australia)

Author keywords

Australia; cost effectiveness; economic modeling; hepatitis C; Markov model

Indexed keywords

PEGINTERFERON; RIBAVIRIN; TELAPREVIR; ANTIVIRUS AGENT; INTERFERON; MACROGOL DERIVATIVE; OLIGOPEPTIDE;

ADULT; AGED; ARTICLE; AUSTRALIA; AUSTRALIAN; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DECOMPENSATED LIVER CIRRHOSIS; DISEASE COURSE; DRUG EFFICACY; FEMALE; HEALTH STATUS; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; LIVER CELL CARCINOMA; LIVER FAILURE; LIVER GRAFT; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REIMBURSEMENT; TREATMENT DURATION; DRUG COMBINATION; ECONOMICS; GENETICS; GENOTYPE; HEPATITIS C, CHRONIC; PROBABILITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL;

ANTIVIRAL AGENTS; AUSTRALIA; DRUG THERAPY, COMBINATION; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; MARKOV CHAINS; MODELS, ECONOMIC; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RIBAVIRIN; SEVERITY OF ILLNESS INDEX;

EID: 84915760316     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2014.07.011     Document Type: Article

References (38)

1. The Kirby Institute (previously National Centre in HIV Epidemiology and Clinical Research). HIV, Viral Hepatitis and Sexually Transmissible Infections in Australia Annual Surveillance Report. Sydney, Australia: The University of New South Wales, 2013
2. Commonwealth of Australia National Hepatitis C Resource Manual 2nd ed. 2008 Department of Health and Ageing Canberra, Australia
3. I. Jacobson, J. McHutchinson, and G. Dusheiko Telaprevir for previously untreated chronic hepatitis C virus infection N Engl J Med 364 2011 2405 2416
4. S. Zeuzem, P. Andreone, and S. Pol Telaprevir for retreatment of HCV infection N Engl J Med 364 2011 2417 2428
5. A. Blazquez-Perez, and R. San Miguel Cost-effectiveness analysis of triple therapy with protease inhibitors in treatment-naïve hepatitis C patients Pharmacoeconomics 31 2013 919 931
6. C. Camma, S. Petta, and G. Cabibbo Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C J Hepatol 59 2013 658 666
7. S. Cure, F. Bianic, and S. Gavart Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in treatment-experienced chronic hepatitis C genotype 1 patients J Med Econ 17 2014 77 87
8. S. Liu, L. Cipriano, and M. Holodniy New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis Ann Intern Med 156 2012 279 290
9. O. Dalgard Follow-up studies of treatment for hepatitis C virus infection among injection drug users Clin Infect Dis 40 Suppl. 5 2005 S336 S338
10. INCIVO (Telaprevir) Australian Product Information. Available from: https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/PICMI?OpenForm&t=pi&q=telaprevir. [Accessed May 19, 2014].
11. VICTRELIS (Boceprevir) Australian Product Information. Available from: https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/PICMI?OpenForm&t=pi&q=boceprevir. [Accessed May 19, 2014].
12. F. Tremolada, C. Casarin, and A. Alberti Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis J Hepatol 16 1992 273 281
13. L. Mattsson, A. Sonnerborg, and O. Weliand Outcome of acute symptomatic non-A, non-B hepatitis: a 13-year follow-up study of hepatitis C virus markers Liver 13 1993 274 278
14. M. Takahashi, G. Yamada, and R. Miyamoto Natural course of chronic hepatitis C Am J Gastroenterol 88 1993 240 243
15. G. Fattovich, G. Giustina, and F. Degos Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients Gastroenterology 112 1997 463 472
16. The Kirby Institute (previously National Centre in HIV Epidemiology and Clinical Research). Epidemiological and Economic Impact of Potential Increased Hepatitis C Treatment Uptake in Australia 2010 The University of New South Wales Sydney, NSW, Australia
17. Australian and New Zealand Liver Transplant Registry. ANZLTR 24th annual report 2012. Available from: http://www.anzltr.org/statistics.html. [Accessed May 19, 2014].
18. Cancer Institute NSW. Cancer survival in NSW 2002-2006. June 2012. Available from: http://www.cancerinstitute.org.au/publications/cancer-survival-in-nsw-2002-06. [Accessed May 19, 2014].
19. Cancer Council Victoria. Cancer in Survival Victoria 2012: estimates of survival for 2006-2010 (and comparisons with earlier periods). 2012. Available from: http://www.cancervic.org.au/research/registry-statistics/cancer-in-victoria. [Accessed May 19, 2014].
20. B. Brady, U. Siebert, and G. Sroczynski Pegylated Interferon Combined with Ribavirin for Chronic Hepatitis C Virus Infection: An Economic Evaluation (Technology report no. 82). 2007 Canadian Agency for Drugs and Technologies in Health Ottawa, Canada (Appendix 4)
21. J. Shepherd, H. Brodin, and C. Cave Pegylated interferon α-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation Health Technol Assess 8 2004 1 140
22. M. Buti, R. San Miguel, and M. Brosa Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C J Hepatol 42 2005 639 645
23. R. San Miguel, J. Mar, and J. Cabase Cost-effectiveness analysis of therapeutic strategies for patients with chronic hepatitis C previously not responding to interferon Aliment Pharmacol Ther 17 2003 765 773
24. J. Chhatwal, S. Ferrante, and C. Brass Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States Value Health 16 2013 973 986
25. Australian Bureau of Statistics, 2010-2012. Available from: http://www.abs.gov.au. [Accessed May 19, 2014].
26. Pharmaceutical Benefits Schedule (PBS). Available from: http://www.pbs.gov.au/pbs/home. [Accessed May 19, 2014].
27. Medicare Benefits Schedule (MBS). Available from: http://www.mbsonline.gov.au/. [Accessed May 19, 2014].
28. Australian Government, Department of Health. AR-DRG cost weights for inpatient episodes, Round 14, version 6.0. Available from: https://www.health.gov.au/internet/main/publishing.nsf/Content/Round-14-cost-reports. [Accessed May 19, 2014].
29. A. Shiell, S. Brown, and G. Farrell Hepatitis C: an economic evaluation of extended treatment with interferon Med J Aust 171 1999 189 193
30. P. Dolan Modeling valuations for EuroQol health states Med Care 35 1997 1095 1108
31. ADVANCE Patient Reported Outcomes Report. Tibotec/Vertex 2010. Cambridge, MA: Vertex Pharmaceuticals Incorporated, 2010.
32. REALIZE Patient Reported Outcomes Report. Tibotec/Vertex 2010. Cambridge, MA: Vertex Pharmaceuticals Incorporated, 2010.
33. M. Wright, R. Grieve, and J. Roberts Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation Health Technol Assess 10 2006 21
34. U. Siebert, G. Sroczynski, and S. Rossol Cost effectiveness of peginterferon (alpha)-2b plus ribavirin versus interferon (alpha)-2b plus ribavirin for initial treatment of chronic hepatitis C Gut 52 2003 425 432
35. L.M. Hagan, Z. Yang, and M. Ehteshami All-oral, interferon-free treatment for chronic hepatitis C: cost-effectiveness analyses J Viral Hepat 20 2013 847 857
36. S.S. El-Kamary, R. Jhaveri, and MD Shardell All-cause, liver-related, and nonliver-related mortality among HCV-infected individuals in the general US population Clin Infect Dis 53 2011 150 157
37. A.H. Harris, S.R. Hill, and G. Chin The role of value for money in public insurance coverage decisions for drugs in Australia: a retrospective analysis 1994-2004 Med Decis Making 28 2008 713 722
38. Australian Government, Department of Health. Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee, version 4.4, June 2013. Available from: http://www.pbac.pbs.gov.au/. [Accessed May 19, 2014].